Publication:
Mid- to long-term outcome of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Data of the BVS registry Göttingen predominantly from ACS patients

Loading...
Thumbnail Image

Date

2017

Authors

Hellenkamp, Kristian
Becker, Alexander
Gabriel, Yannick D.
Hasenfuss, Gerd
Hünlich, Mark
Jacobshagen, Claudius
Schillinger, Wolfgang
Schroeter, Marco R.

Journal Title

Journal ISSN

Volume Title

Publisher

Research Projects

Organizational Units

Journal Issue

Abstract

Background Bioresorbable vascular scaffolds (BVS) are widely used in routine clinical practice. While previous studies reported acceptable short- to midterm outcome after BVS implantation, data on longer-term outcome are rare. Methods Patients treated with at least one Absorb®-BVS were consecutively enrolled. Follow-up data were assessed after 834.0 [769.0–1026.0] days. The primary device-oriented composite endpoint (DOCE) was defined as cardiovascular death, myocardial infarction (MI) and/or target lesion revascularization (TLR). Results Between 2012 and 2014, 195 patients were included into study analysis. Overall, 244 BVS were implanted. Mean patient age was 64.0[54.3–74.0] years. Three-quarter of patients had an ACS; of those 42.9% had ST-elevation-MI and 40.8% had non-ST-elevation-MI. DOCE occurred in 3.1%, 6.7%, 11.8% and 15.4% of patients during hospital stay, within 6-months, 18-months or during the complete follow-up period, respectively. In those patients, median time until DOCE was 211.5[43.25–567.25] days. In 11 (36.7%) patients DOCE occurred after > 12 months. Using univariable analysis, bifurcation stenting was associated with a hazard ratio (HR) of 11.8[2.38–58.57] for TLR (p = 0.002) and 2.1[1.02–4.49] for DOCE (p = 0.045). Similarly, in ACS patients, bifurcation stenting was associated with an increased risk for TLR (HR = 10.4[2.01–53.56]; p = 0.005) and for DOCE (HR = 2.4[1.09–5.32]; p = 0.029) and in multivariable analysis, it remained an independent predictor of DOCE (HR = 3.0; p = 0.018). Conclusions Although, the rates of (potentially) device-related complications following BVS implantation are acceptable, they are nonetheless not negligible. Interestingly, they did not decline over time. Bifurcation stenting could be found as relevant procedure-related predictor of DOCE, especially in ACS patients. Randomized trials are warranted to confirm these findings.

Description

Keywords

Citation

Collections

Endorsement

Review

Supplemented By

Referenced By